

**Shipp, Allan (OD)**

---

**From:** Patterson, Amy (OD)  
**Sent:** Wednesday, October 30, 2002 11:03 PM  
**To:** Rosenthal, Eugene (OD); Rose, Stephen (OD)  
**Cc:** Powell, Penny (OD); Carr, Sarah (OD); Shipp, Allan (OD); Lanman, Robert (OD)  
**Subject:** RE: IBC approval for NIH OBA protocol number 9909-341

I would like to meet to follow up on this in the next two weeks.

Steve,

You were going to prepare a timeline on the Tisdale submission, right?

Amy

**Amy P. Patterson, M.D.**  
Director  
Office of Biotechnology Activities  
Office of Science Policy  
Office of the Director  
National Institutes of Health  
6705 Rockledge Drive, Suite 700  
Bethesda, MD 20892

Failure to obtain IBC Approval prior to enrollment of subject on human gene transfer protocol #341.

tel (301) 496-9838  
fax (301) 496-9839  
e-mail: pattersa@od.nih.gov

-----Original Message-----

**From:** Rosenthal, Eugene (OD)  
**Sent:** Monday, October 28, 2002 5:05 PM  
**To:** Patterson, Amy (OD); Rose, Stephen (OD)  
**Subject:** FW: IBC approval for NIH OBA protocol number 9909-341

FYI...Response from Dr. Tisdale

-----Original Message-----

**From:** Tisdale, John (NIH/NIDDK)  
**Sent:** Monday, October 28, 2002 5:01 PM  
**To:** Rosenthal, Eugene (OD)  
**Subject:** RE: IBC approval for NIH OBA protocol number 9909-341

Dear Dr Rosenthal,

Thank you for your prompt follow-up. As I stated, we are no longer pursuing this strategy, but I was responding to an inquiry from Sandra Bridges in NIAID.

Regards,  
John

-----  
**From:** Rosenthal, Eugene (OD)  
**Sent:** Monday, October 28, 2002 4:48 PM  
**To:** Tisdale, John (NIH/NIDDK)  
**Cc:** Patterson, Amy (OD); Rose, Stephen (OD)  
**Subject:** IBC approval for NIH OBA protocol number 9909-341

Dear Dr. Tisdale,

As a follow-up to our phone conversation today, I checked our protocol file and we did receive a faxed copy, recently, of the IBC approval for your human gene transfer trial entitled: "Low Intensity Non-Myeloablative Preparative Conditioning Followed by Transplantation of Genetically Modified HLA-Matched Peripheral Blood Hematopoietic Precursor Cells (PBPC) for Hematologic Malignancies in HIV Positive Adults" (NIH OBA protocol number 9909-341). Protocol 9909-341 was submitted to the Office of Biotechnology Activities back in September 1999.

Sincerely,  
Eugene Rosenthal, Ph.D.  
Biotechnology Program Advisor  
Office of Biotechnology Activities  
National Institutes of Health  
6705 Rockledge Drive, Suite 750  
Bethesda, Maryland 20892  
(20892 for USPS only;  
please use 20817 for other  
delivery methods)  
301-496-9838  
301-496-9839 fax  
rosenthg@od.nih.gov